B. Riley initiated coverage of Zymeworks (ZYME) with a Buy rating and $30 price target The firm views Zymeworks as a multifunctional therapeutics biotech with “highly differentiated” and “clinically de-risked” therapies. It expects Ziihhera to expand into gastric and breast cancer. The upcoming Jazz Pharmaceuticals (JAZZ) Phase 3 HERIZON-GEA readout to present potential upside to the Street’s estimates, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks Appoints New Acting Chief Development Officer to Boost Therapeutic Advancements
- Zymeworks appoints Adam Schayowitz as Acting Chief Development Officer
- Zymeworks’ Zanidatamab Shows Promising Potential in HERIZON-GEA-01 Trial with Significant Stock Upside
- Strategic Shift to Zanidatamab Drives Optimistic Buy Rating for Zymeworks
- Strategic Focus and Promising Pipeline Drive Buy Rating for Zymeworks